Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors-Reference-Cited by-同舟云学术

Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors

Published:2018-02-28 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Chepurny Oleg G.,Bonaccorso Ron L.,Leech Colin A.,Wöllert Torsten,Langford George M.,Schwede Frank,Roth Christian L.,Doyle Robert P.^ORCID,Holz George G.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-22106-1.pdf

Reference68 articles.

1. Frias, J. P. et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab. 26, 343–352 (2017).

2. Dalboge, L. S. et al. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases beta-cell mass without affecting islet number in db/db mice. J. Pharmacol. Exp. Ther. 350, 353–360 (2014).

3. Sanchez-Garrido, M. A. et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60, 1851–1861 (2017).

4. Kim, G. W., Lin, J. E., Blomain, E. S. & Waldman, S. A. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin. Pharmacol. Ther. 95, 53–66 (2014).

5. Holz, G. G. & Chepurny, O. G. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr. Med. Chem. 10, 2471–2483 (2003).

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Brain–Heart Network of Syncope;International Journal of Molecular Sciences;2024-06-26

2. Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis;Neuropeptides;2024-06

3. The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner;2024-05-21

4. Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity;Peptides;2023-11

5. Molecular hybridization strategy for tuning bioactive peptide function;Communications Biology;2023-10-19